Download PDF

1. Company Snapshot

1.a. Company Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.


The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder.The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc.Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Show Full description

1.b. Last Insights on JAZZ

Breaking News: Jazz Pharmaceuticals reported Q4 earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago. The company's revenue also surpassed estimates, driven by strong sales in neuroscience and oncology. The positive earnings report led to a recommendation to buy the stock from some analysts. According to recent news, the company's Q4 earnings and sales top expectations. A recent analysis also considered key metrics compared to Wall Street estimates and year-ago numbers.

1.c. Company Highlights

2. Jazz Pharmaceuticals' Record Revenue and Growth in 2025

Jazz Pharmaceuticals reported record total revenue of $4.3 billion in 2025, representing 5% growth over 2024, with a non-GAAP adjusted EPS of $8.38. The company's fourth-quarter revenue was $1.2 billion, driven primarily by 16% growth in Xywav and strong initial uptake of Modeyso. The actual EPS came out at $6.64, slightly beating estimates of $6.62. The strong revenue growth was largely attributed to the company's diversified portfolio, with Xywav revenue growing 12% to approximately $1.7 billion for the year, and Epidiolex reaching blockbuster status with $1.1 billion in revenue. As Sam Pearce, Chief Commercial Officer, noted, the company demonstrated "strong execution across the diversified portfolio in 2025."

Publication Date: Feb -26

📋 Highlights
  • Record Revenue: 2025 total revenue hit $4.3 billion, with 10% Q4 YoY growth ($1.2 billion Q4 revenue).
  • Modeyso Launch Success: Generated $48 million in 2025, 4.5 months post-launch, targeting a $500 million peak sales opportunity.
  • Epidiolex Blockbuster Status: Achieved $1.1 billion in 2025 revenue, with 7% volume growth driven by strong demand.
  • Xywav Growth Momentum: Revenue grew 12% to $1.7 billion in 2025, 16% Q4 growth, with $1.8–$1.9 billion guidance for 2026.
  • 2026 Guidance: Targets $4.25–$4.5 billion revenue (2.5% growth midpoint), 90–91% non-GAAP gross margin, and $725–$775 million R&D spend.

Segment-wise Performance

The company's rare oncology and epilepsy revenues are expected to drive double-digit growth in 2026, primarily driven by Epidiolex, Modeyso, and Ziihera. The launch of Modeyso has been successful, generating $48 million in revenue in 2025, just 4.5 months into the launch. The company is increasingly confident about the $500 million peak sales opportunity for Modeyso, assuming the ACTION study is successful.

Pipeline and Development Programs

The company has a robust pipeline, with several promising development opportunities, including JZP047, which has been cleared to proceed into a Phase I study for the treatment of absence epilepsy. The company has also initiated a Phase Ib trial of Epidiolex in focal onset seizures and is developing zanidatamab across multiple tumor types, with an expected launch in GEA in the second half of 2026.

Valuation and Outlook

With a P/E Ratio of -33.7 and an EV/EBITDA of 83.75, the company's valuation appears to be stretched. However, the company's strong revenue growth and pipeline opportunities may justify the premium. Analysts estimate next year's revenue growth at 8.7%, which may provide a positive catalyst for the stock. The company's guidance range for 2026 is $4.25 billion to $4.50 billion in total revenue, representing 2.5% growth at the midpoint compared to 2025.

Financial Health

The company's balance sheet remains strong, with $2.4 billion in cash and investments at the end of 2025. The company continues to generate significant cash from its business and has the flexibility to invest in value-driving commercial and R&D programs, as well as in promising corporate development opportunities.

3. NewsRoom

Card image cap

Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know

Mar -02

Source: zacks.com

Card image cap

Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?

Feb -27

Source: zacks.com

Card image cap

Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More

Feb -27

Source: 247wallst.com

Card image cap

Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook

Feb -26

Source: seekingalpha.com

Card image cap

JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations

Feb -25

Source: zacks.com

Card image cap

Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript

Feb -25

Source: seekingalpha.com

Card image cap

Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Feb -25

Source: zacks.com

Card image cap

Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates

Feb -25

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.00%)

6. Segments

Pharmaceutical Products

Expected Growth: 5.0%

Jazz Pharmaceuticals' 5.0% growth in Pharmaceutical Products is driven by increasing demand for its sleep disorder treatments, Xyrem and Sunosi, as well as growing sales of its cancer therapy, Vyxeos. Additionally, the company's strategic acquisitions and partnerships, such as its deal with PharmaMar, have expanded its product portfolio and enhanced its R&D capabilities.

7. Detailed Products

Xyrem

A sodium oxybate oral solution used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Erwinaze

A asparaginase enzyme used to treat acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase.

Vyxeos

A liposomal formulation of daunorubicin and cytarabine used to treat adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Defitelio

A defibrotide sodium injection used to treat severe hepatic veno-occlusive disease (VOD) in patients who have undergone hematopoietic stem cell transplantation.

Zygel

A transdermal cannabidiol gel used to treat Fragile X syndrome, a rare genetic disorder.

8. Jazz Pharmaceuticals plc's Porter Forces

Forces Ranking

Threat Of Substitutes

Jazz Pharmaceuticals plc has a moderate threat of substitutes due to the presence of alternative treatments and therapies for sleep disorders and oncology.

Bargaining Power Of Customers

Jazz Pharmaceuticals plc has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative suppliers.

Bargaining Power Of Suppliers

Jazz Pharmaceuticals plc has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and manufacturing services.

Threat Of New Entrants

Jazz Pharmaceuticals plc has a high threat of new entrants due to the growing demand for sleep disorders and oncology treatments, making it an attractive market for new entrants.

Intensity Of Rivalry

Jazz Pharmaceuticals plc operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 60.54%
Debt Cost 4.32%
Equity Weight 39.46%
Equity Cost 7.09%
WACC 5.41%
Leverage 153.40%

11. Quality Control: Jazz Pharmaceuticals plc passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Genmab

A-Score: 5.8/10

Value: 3.2

Growth: 9.7

Quality: 9.5

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
ALK-Abelló

A-Score: 5.0/10

Value: 0.2

Growth: 8.2

Quality: 7.8

Yield: 0.0

Momentum: 9.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Alkermes

A-Score: 5.0/10

Value: 4.9

Growth: 8.4

Quality: 8.9

Yield: 0.0

Momentum: 4.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Jazz Pharmaceuticals

A-Score: 4.9/10

Value: 4.8

Growth: 7.1

Quality: 4.7

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Merus

A-Score: 3.5/10

Value: 6.0

Growth: 1.8

Quality: 3.4

Yield: 0.0

Momentum: 9.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Zealand Pharma

A-Score: 3.3/10

Value: 7.0

Growth: 2.2

Quality: 9.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

190.46$

Current Price

190.46$

Potential

-0.00%

Expected Cash-Flows